These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 30028337)

  • 21. Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. The PKDS009 Study Group.
    Rinne UK; Bracco F; Chouza C; Dupont E; Gershanik O; Marti Masso JF; Montastruc JL; Marsden CD
    Drugs; 1998; 55 Suppl 1():23-30. PubMed ID: 9483167
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Amantadine extended release for levodopa-induced dyskinesia in Parkinson's disease (EASED Study).
    Pahwa R; Tanner CM; Hauser RA; Sethi K; Isaacson S; Truong D; Struck L; Ruby AE; McClure NL; Went GT; Stempien MJ
    Mov Disord; 2015 May; 30(6):788-95. PubMed ID: 25650051
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Early institution of bromocriptine in Parkinson's disease inhibits the emergence of levodopa-associated motor side effects. Long-term results of the PRADO study.
    Przuntek H; Welzel D; Gerlach M; Blümner E; Danielczyk W; Kaiser HJ; Kraus PH; Letzel H; Riederer P; Uberla K
    J Neural Transm (Vienna); 1996; 103(6):699-715. PubMed ID: 8836932
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Acupuncture for early Parkinson's disease with mild to moderate depression: a randomized controlled trial protocol with functional MRI.
    Xiao H; Ren Y; Yang H; Wang Z; Li Z; Song Y; Yuan X; Liu X; Chen P
    Front Neurol; 2024; 15():1457787. PubMed ID: 39430584
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tozadenant (SYN115) in patients with Parkinson's disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trial.
    Hauser RA; Olanow CW; Kieburtz KD; Pourcher E; Docu-Axelerad A; Lew M; Kozyolkin O; Neale A; Resburg C; Meya U; Kenney C; Bandak S
    Lancet Neurol; 2014 Aug; 13(8):767-76. PubMed ID: 25008546
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of rotigotine transdermal patch in patients with Parkinson's disease presenting with non-motor symptoms - results of a double-blind, randomized, placebo-controlled trial.
    Antonini A; Bauer L; Dohin E; Oertel WH; Rascol O; Reichmann H; Schmid M; Singh P; Tolosa E; Chaudhuri KR
    Eur J Neurol; 2015 Oct; 22(10):1400-7. PubMed ID: 26095948
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial.
    Rascol O; Brooks DJ; Melamed E; Oertel W; Poewe W; Stocchi F; Tolosa E;
    Lancet; 2005 Mar 12-18; 365(9463):947-54. PubMed ID: 15766996
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
    Athauda D; Maclagan K; Skene SS; Bajwa-Joseph M; Letchford D; Chowdhury K; Hibbert S; Budnik N; Zampedri L; Dickson J; Li Y; Aviles-Olmos I; Warner TT; Limousin P; Lees AJ; Greig NH; Tebbs S; Foltynie T
    Lancet; 2017 Oct; 390(10103):1664-1675. PubMed ID: 28781108
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effectiveness of home-based and remotely supervised aerobic exercise in Parkinson's disease: a double-blind, randomised controlled trial.
    van der Kolk NM; de Vries NM; Kessels RPC; Joosten H; Zwinderman AH; Post B; Bloem BR
    Lancet Neurol; 2019 Nov; 18(11):998-1008. PubMed ID: 31521532
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safinamide as Add-On Therapy to Levodopa in Mid- to Late-Stage Parkinson's Disease Fluctuating Patients: Post hoc Analyses of Studies 016 and SETTLE.
    Cattaneo C; Sardina M; Bonizzoni E
    J Parkinsons Dis; 2016; 6(1):165-73. PubMed ID: 26889632
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Randomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson's disease (EASE LID 3).
    Oertel W; Eggert K; Pahwa R; Tanner CM; Hauser RA; Trenkwalder C; Ehret R; Azulay JP; Isaacson S; Felt L; Stempien MJ
    Mov Disord; 2017 Dec; 32(12):1701-1709. PubMed ID: 28833562
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Significant improvement of motor symptoms by deep brain stimulation of bilateral subthalamic nucleus in patients with moderate or advanced Parkinson's disease].
    Chen J; Liu JL; Chen X; Qian H; Xian WB; Zhou HY; Liu YM; Ye XF; Zheng YF; Zhang SL; Chen L; Li JR; Liu ZL; Pei Z
    Zhonghua Yi Xue Za Zhi; 2011 Feb; 91(5):291-5. PubMed ID: 21419000
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ropinirole versus bromocriptine for levodopa-induced complications in Parkinson's disease.
    Clarke CE; Deane KH
    Cochrane Database Syst Rev; 2001; (1):CD001517. PubMed ID: 11279719
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bromocriptine versus levodopa in early Parkinson's disease.
    Ramaker C; van Hilten JJ
    Cochrane Database Syst Rev; 2000; (3):CD002258. PubMed ID: 10908538
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Randomized Delayed-Start Trial of Levodopa in Parkinson's Disease.
    Verschuur CVM; Suwijn SR; Boel JA; Post B; Bloem BR; van Hilten JJ; van Laar T; Tissingh G; Munts AG; Deuschl G; Lang AE; Dijkgraaf MGW; de Haan RJ; de Bie RMA;
    N Engl J Med; 2019 Jan; 380(4):315-324. PubMed ID: 30673543
    [TBL] [Abstract][Full Text] [Related]  

  • 36. AFQ056 treatment of levodopa-induced dyskinesias: results of 2 randomized controlled trials.
    Berg D; Godau J; Trenkwalder C; Eggert K; Csoti I; Storch A; Huber H; Morelli-Canelo M; Stamelou M; Ries V; Wolz M; Schneider C; Di Paolo T; Gasparini F; Hariry S; Vandemeulebroecke M; Abi-Saab W; Cooke K; Johns D; Gomez-Mancilla B
    Mov Disord; 2011 Jun; 26(7):1243-50. PubMed ID: 21484867
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical Efficacy and Transcriptomic Analysis of Congrong Shujing Granules () in Patients with Parkinson's Disease and Syndrome of Shen (Kidney) Essence Deficiency.
    Chen SY; Xiao SJ; Lin YN; Li XY; Xu Q; Yang SS; Huang LH; Cai J
    Chin J Integr Med; 2020 Jun; 26(6):412-419. PubMed ID: 32291608
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy, safety, and tolerability of pramipexole in untreated and levodopa-treated patients with Parkinson's disease.
    Wong KS; Lu CS; Shan DE; Yang CC; Tsoi TH; Mok V
    J Neurol Sci; 2003 Dec; 216(1):81-7. PubMed ID: 14607306
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial.
    Ferreira JJ; Lees A; Rocha JF; Poewe W; Rascol O; Soares-da-Silva P;
    Lancet Neurol; 2016 Feb; 15(2):154-165. PubMed ID: 26725544
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Rating scale and functional prognosis of Parkinson's disease].
    Nakano I; Fujimoto K
    Nihon Rinsho; 2000 Oct; 58(10):2132-8. PubMed ID: 11068460
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.